U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07181161) titled 'Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer' on Sept. 12.
Brief Summary: The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.
Study Start Date: Sept. 22
Study Type: INTERVENTIONAL
Condition:
Metastatic Prostate Cancer
Intervention:
DRUG: AZD0516
AZD0516 will be administered via intravenous infusion.
DRUG: AZD9574
AZD9574 will be administered orally.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: AstraZeneca
Published by HT Di...